Chang et al., present a cross-sectional study including 397 schizophrenia and related psychoses patients from a tertiary psychiatric hospital in Singapore. One in tenth of the patients reported problematic drug and/or alcohol use. This rate is relatively lower than the rates reported in western countries (1, 2). However, problematic drug/alcohol use is associated with greater mental distress and poor physical health in psychosis spectrum patients, in line with substantial evidence from different parts of the world (3–8).

To date, a considerable number of longitudinal studies have been conducted to elucidate the associations between substance use and psychosis (9–11). However, evidence on momentary dynamic associations between substance use and psychosis in daily life is scant. Weiss et al. present an interesting study using the experience-sampling methodology (ESM). In this study, youth with clinical high risk (CHR) or early psychosis (EP) provided data on substance use, psychotic symptoms, and negative affect six times a day via a smartphone application. Results showed that substance use was significantly associated with lagged negative affect. With relatively larger sample sizes and longer follow-up periods, ESM seems to be a promising tool to provide insight into moment-to-moment associations between substance use and psychosis.

Over the last two decades, clinicians struggle with the increased incidence of methamphetamine and ketamine induced psychoses across the world (12–14). However, our insight into this relatively “recent” crisis is limited. Luo et al. compared different features of psychotic symptoms between users of these drugs (n = 842). After at least two weeks of drug abstinence, psychotic symptoms were reported by three quarters of methamphetamine use disorder (MUD) patients and half of ketamine use disorder (KUD) patients. MUD patients were more likely to experience positive psychotic symptoms, as well as stereotyped thinking, difficulty in abstraction withdrawal, and poor rapport than KUD patients, whereas general symptoms, such as sleep and anxiety, were similar across the two groups.

This article collection includes novel studies on the neurobiological underpinnings of substance use-psychosis comorbidity. Johnstone et al. systematically reviewed the evidence on the clinical utility of neuromodulation techniques to treat comorbid substance use and psychosis spectrum disorder. Authors concluded that preliminary evidence supported the effectiveness of repetitive transcranial magnetic stimulation (rTMS) targeting the dorsolateral prefrontal cortex (DLPFC), a well-known brain region involved in top-down regulation, on reducing cannabis and tobacco use in patients with schizophrenia and schizoaffective disorder. However, some studies showed no significant effect of rTMS on reducing cannabis and tobacco use in this population, as also presented by Ward, Brady et al. in their mini review. An original fMRI study by Ward, Beermann et al. showed that nicotine use might normalize default mode network hyperconnectivity in patients with schizophrenia. Default mode network hyperconnectivity was previously associated with impaired attention. Considering the plausible unique pro-cognitive effect of nicotine use in patients with schizophrenia, this article suggested targeting the default mode network hyperconnectivity for smoking cessation in schizophrenia patients. Finally, Hau et al. presented a brief research report demonstrating a positive or borderline result of anti-neuronal autoantibodies in one-third of synthetic cannabinoid-induced psychosis patients. However, no significant association was found between PANSS scores and the presence of anti-neural antibodies in this study. These results require replication in larger samples.

One of the major challenges in psychiatry is the relatively low treatment adherence in patients with comorbid substance use disorders and psychosis spectrum disorder. Bouchard et al. present a comprehensive systematic review and meta-analysis of available evidence for dropout rates in psychosocial interventions for this population. Results showed that more than a quarter of these patients dropped out from psychosocial treatments with even higher rates among patients with stimulant use disorder. Long acting injectable antipsychotics (LAIs) might help cope with high drop-out rates. Coles et al. presented a systematic review of the literature investigating the use of LAIs in this population. Preliminary evidence suggests that LAIs might be safe, well tolerated, and mostly effective in the treatment of psychosis spectrum and substance use comorbidity. Furthermore, Gjerde et al. presented an original study demonstrating that cannabis use in patients with first treatment psychosis was not significantly associated with negative beliefs about antipsychotic medication. This preliminary result suggests that favorable treatment adherence may be achieved in comorbid psychosis spectrum and substance use disorder patients, if other reasons for non-adherence (e.g., lack of insight, side effects) are taken into account.